In one aspect, methods of treating non-alcoholic steatohepatitis (NASH) or preventing or delaying the progression of non-alcoholic fatty liver disease (NAFLD) to NASH are provided. In some embodiments, the method comprises administering a therapeutically effective amount of pirfenidone. In some embodiments, the method comprises administering therapeutically effective amounts of pirfenidone and ubenimex as part of a combination therapy.
